A Pilot Study of Topiramate in Childhood Absence Epilepsy
Epilepsy, Absence
About this trial
This is an interventional treatment trial for Epilepsy, Absence focused on measuring childhood absence epilepsy, epilepsy, seizures, absence seizures
Eligibility Criteria
Inclusion Criteria: Weight of at least 15 kg (33 pounds) confirmed diagnosis of childhood absence epilepsy no other serious health problems or neurologic problems have not taken anti-epilepsy drugs other than ethosuximide, lamotrigine, or valproate able to take oral medication in a sprinkle capsule formulation girls must not have gotten their first menstrual period. Exclusion Criteria: No seizures that are caused by something other than childhood absence epilepsy not taken topiramate, primidone, zonisamide, or phenobarbital in the past had to stop taking an anti-epilepsy drug (ethosuximide, lamotrigine, or valproate) because it was not effective in treating childhood absence epilepsy no presence of abnormal brain waves on electroencephalogram no presence of mental retardation, no autism, or severe developmental disorder.